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Abstract
Background: In German breast cancer care, the S1-guidelines of the 1990s were substituted by national S3-guidelines
in 2003. The application of guidelines became mandatory for certified breast cancer centers. The aim of the study was
to assess guideline adherence according to time intervals and its impact on survival.
Methods: Women with primary breast cancer treated in three rural hospitals of one German geographical district were
included. A cohort study design encompassed women from 1996–97 (N = 389) and from 2003–04 (N = 488). Quality
indicators were defined along inpatient therapy sequences for each time interval and distinguished as guideline-
adherent and guideline-divergent medical decisions. Based on all of the quality indicators, a binary overall adherence
index was defined and served as a group indicator in multivariate Cox-regression models. A corrected group analysis
estimated adjusted 5-year survival curves.
Results: From a total of 877 patients, 743 (85 %) and 504 (58 %) were included to assess 104 developed quality
indicators and the resuming binary overall adherence index. The latter significantly increased from 13–15 %
(1996–97) up to 33–35 % (2003–04). Within each time interval, no significant survival differences of guideline-adherent
and -divergent treated patients were detected. Across time intervals and within the group of guideline-adherent
treated patients only, survival increased but did not significantly differ between time intervals. Across time intervals and
within the group of guideline-divergent treated patients only, survival increased and significantly differed between time
intervals.
Conclusions: Infrastructural efforts contributed to the increase of process quality of the examined certified breast
cancer center. Paradoxically, a systematic impact on 5-year survival has been observed for patients treated divergently
from the guideline recommendations. This is an indicator for the appropriate application of guidelines. A maximization
of guideline-based decisions instead of the ubiquitous demand of guideline adherence maximization is advocated.
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Background
Breast cancer (BC) is the most frequent female malig-
nancy with approximately 1.65 million diagnosed women
worldwide [1, 2]. Growing incidence and decreasing
mortality rates are reported for developed countries. In
Germany, general trends are confirmed and today, sur-
vival after BC is higher than in the 1990s [3].
Guidelines before 2000
There are many reasons for these trends. The increasing
effectiveness of therapy itself is certainly one crucial factor
[4]. However, it is critical to distribute and implement
published research from clinical trials into daily routine in
a comprehensive manner. In the past, a small number of
experts (St. Gallen consensus panel) interpreted actual re-
sults of trials and published the current state-of-the-art
BC treatment [5–7]. Additionally, national [8] or Euro-
pean guidelines [9] provided treatment recommendations
for physicians willing to improve their skills. Low accept-
ance and arbitrary application of these S1-guidelines were
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the norm, not the exception [10]. BC treatment depended
mainly on experiences and knowledge of the physician.
Counseling colleagues or quality circles met irregularly
and the availability of expertise from other (medical) disci-
plines involved in the BC treatment was not institutional-
ized. Overall, health care professionals of different settings
cooperated in a “free interplay” (e.g., liberally organized
market) within a fragmented, but competitive German
health care system [11].
Guidelines after 2000
A common effort of all stakeholders intended to overcome
these deficits and developed evidence-, consensus-, and
outcome-based national guidelines for the early detection
[10] and therapy [12] of BC. The application of these
S3-guidelines was mandatory for centralized BC networks
inspired by so called “hub & spoke” models [13–15]. Hubs
were defined by academic institutions, and spokes
refer to all of the related health care professionals. A
network-wide monitoring of guideline application was
assured by quality management systems, which be-
came officially certified [13]. Multidisciplinary counseling
was assured by expert panels (tumor conferences) hosted at
comprehensive cancer centers. Integrated care models [16]
were developed to overcome aforementioned infrastruc-
tural deficits.
Effectiveness of guidelines
Only a few studies have focused on all (inpatient) ther-
apy sequences, guideline adherence and its impact on
outcome measures. In Germany, the studies of Woeckel
et al. [17, 18] examined this topic and confirmed the
general effectiveness of guideline adherence using time
intervals 1992–2005. Based on these data, authors called
for the maximization of guideline adherence.
This approach is straightforward and yields two critical
assumptions. First, study design might be appropriate as
long as the general effectiveness of S3-guidelines is of
concern. However, if the appropriateness of medical de-
cisions according to released and concurrent guidelines
is of interest, the above mentioned approach is not ad-
equate. S3-Guidelines were not released before 2003,
and therefore time effects induced by different guidelines
cannot be captured.
Second, the concluded guideline maximization hypoth-
esis was based on the assumption that medical decisions
adherent to the guidelines is appropriate. This assumption
is true if all of the physical and mental conditions of the pa-
tient agree with clinical algorithms, ancillary conditions,
and patients’ preferences. However, if one of these premises
is not fulfilled, the physicians are encouraged to decide
against guideline recommendations [10, 12].
Aim of the study
The objective of the study is to exam the impact of
process quality on 5-year overall survival. But in contrast to
the above mentioned studies, process quality is assessed ac-
cording to operating guidelines of time intervals (1996–97,
2003–04). Guideline adherence and divergence should be
measured by a set of quality indicators defined along in-
patient therapy sequences and related medical decisions.
An overall adherence index is developed and two questions
are examined: Is there a difference between guideline ad-
herent and guideline divergent treated patients in terms of
survival, first, within each time interval, and second, across
time intervals? It is hypothesized that process quality in-
creased over time. But in contrast to the cohort 1996–97,
we expect an impact of process quality on survival for the
cohort 2003–04. With respect to cross-period analysis, we
expect higher survival of patients treated adherent to guide-
lines in 2003–04 and no survival differences of patients
treated divergent from guidelines.
Methods
Incidence-based full population survey
All women with primary BC treatment in two general
hospitals and one specialized academic hospital located
in the district of Marburg-Biedenkopf (Hesse, Germany)
were included (entry cohort). Patients were identified by
surgical schedule lists and attendant histological affirm-
ation of BC (ICD-10: C.50). Physicians recruited patients
by explaining the aims of the study and obtained written
informed consent. The relevant data were extracted
from patient record files and stored in a clinical register
[19–21]. The study was approved and conducted according
to the Declaration of Helsinki and the local ethics commit-
tee of the Philipps University of Marburg (Germany).
Sample selection for analysis
The entry cohort encompassed all treated patients (total
“workload”), but not all patients of the entry cohort
could be analysed by standardized quality indicators.
Therefore, heterogeneous patient collectives with non-
invasive tumours (pTis) and with distant metastasis or
unknown metastasis status were dropped from further
analysis to consider individual medical needs and the
complexity of each therapy. This step defined the
institutional-invasive samples. These were corrected by
identifying non-resident patients to define regional-
invasive samples [19–21].
Exposure of cohorts
Cohort 1996–97 was exposed to the “free-interplay” of
institutions. Primary BC treatment followed the S1-
guidelines [6–9]. Cohort 2003–04 was exposed to an
“integrated care” model defined by a certified BC center
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[13]. Primary BC treatment followed recommendations
of the national S3-guidelines [10].
Primary endpoint and follow-up
Five-year overall survival regardless of causes of death
was defined as the primary endpoint. The start of the
observation time was the date of surgical intervention.
The verification of the vital status was assessed by the
official registry office corresponding to each inpatient.
Follow-up began in 10/2008 and ended in 2/2009.
Covariates for risk adjustments
Available risk factors, prognostic and predictive factors
for BC [22] were integrated into the Cox model. Regres-
sors of the final model were: age at surgical intervention,
binary nodal status, binary tumour size, binary hormone
receptor status, and binary adherence index. The infor-
mation on treatment location and application of chemo-
therapy served as strata variables.
Quality indicators of medical decision-making
Quality indicators were defined alongside relevant in-
patient treatment sequences: surgical intervention (tumor,
lymph nodes) together with radio-oncological irradiation,
and chemo- and hormone-therapy according to different
risk categories [7, 12]. Pre-operative diagnostic sequences
and other systemic interventions (e.g., HER2neu among
others) were not available in 1996–97 and were excluded.
Quality indicators (QI) operationalized guideline recom-
mendations in two categories. First, recommendations that
should be respected by physicians if all other ancillary
conditions are fulfilled were one category. This QI cat-
egory translated to Guideline Adherent Decisions (GAD).
Second, medical decisions against recommendations
of the guidelines were defined by Guideline Divergent
Decisions (GDD). It is important to note that GADs
and GDDs are not always the opposite of each other
(e.g., not disjunctive). For the definition of QIs accord-
ing to the S1-guidelines (1996–97) and S3-guidelines
(2003–04), short and long descriptions are provided
(see Additional files 1 and 2).
Adherence index
Developed QIs were aggregated into four indices con-
cerning the adherence status of every therapy sequence.
However, all QIs contributed to one overall binary ad-
herence index. The aggregation of QIs was performed by
the following methodology. First, each QI was assessed
according to its category (GAD, GDD). Second, if all
GADs were assessed as positive (e.g., adherent), BC
treatment of one patient was preliminarily considered to
be guideline adherent by the summarizing overall adher-
ence index. But, if even one GAD did not catch up with
guideline recommendations, the adherence index was
devalued and considered to be guideline-divergent. Third,
even when one GDD was administered as positive (e.g., di-
vergent), inpatient primary BC therapy was classified as
guideline-divergent by the overall adherence index. In this
sense, only one disrespected quality indicator devalued all
possible guideline-adherent indicators beforehand.
Statistics
Univariate statistics describe clinical characteristics of the
selected samples. The distributions of covariates between
cohorts were compared by Chi-square-, Kruskall- Wallis-,
Mantel-Haentszel Chi-square, Mann–Whitney U- or T-
Tests. Derived p- values were adjusted for multiple testing
by the Bonferroni-Holm method. Frequency counts de-
scribed quality indicators, and Chi-Square tests adjusted for
multiple testing with the Bonferroni-Holm method were
applied. Multivariate survival analysis was performed by a
Cox-regression model [23]. Multivariate survival curves
were derived by the corrected group analysis method [24].
The significance level was defined by α = 5 %. SAS 9.3 soft-
ware was used.
Analysis strategy
Univariate results of sampling and distributions of im-
portant covariates are presented first. The number of de-
veloped quality indicators and their guideline adherence
(divergence) of each therapy sequence and of the overall
binary adherence index are presented. Finally, multivari-
ate survival methods analyzed every period (e.g., cohort)
separately, before cross-period/cohort comparisons without
the adherence index and cross-period/-cohort comparisons
conditioning on adherence status were performed.
Results
Sampling results
An entry cohort of 877 patients was reduced by 134
patients (15 %) due to loss to follow-up (1.9 %), non-
assessable stage information (0.3 %), non-invasive tumours
(6.3 %), non-assessable or distant metastases (5.2 %), or
non-assessable margins of removed tumours (1.5 %). Ex-
cluded patients were randomly distributed over both co-
horts (see percentages of Table 1), and no significant
differences between included and excluded patients were
detected (p-values not shown here). The exclusion of pa-
tient records left 743 (84.7 %) in the institutional-invasive
samples and 504 (57.5 %) patients in the regional-invasive
samples for analysis.
Descriptive statistics
Distributions of available risk, prognosis and predictive
factors showed roughly balanced samples between cohorts
(e.g., time intervals). Exceptions in the institutional-invasive
sample refer to cohort 1996–97, which showed more
invasive-ductal carcinomas (84 % vs 73 % in 2003–04),
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fewer G2- (48 % vs 71 %) and more G3-types (45 % vs
15 %), less R0-resection margins (85 % vs 95 %), and fewer
patients from clinic C (63 % vs 80 %). A similar pattern was
evident in the regional-invasive sample (see Table 2 for
details).
Process quality indicators
In total, 104 quality indicators defined Guideline Adherent
Decisions (51) and Guideline Divergent Decisions (53).
Common QIs valid for both cohorts due to equal guide-
line recommendations related to the surgical strategy. A
total number of 23 QIs referred to the sequences of breast
conserving surgery and irradiation (BCS + RAD: 8 QIs)
and the modified radical mastectomy (15 QIs).
The remaining QIs differed between time intervals,
and cohort-specific conceptualization of QIs was required.
Axilla treatment (1996–97: 2, 2003–04: 9) differed due to
implementation of sentinel techniques in period 2003–04.
Chemo- and hormone- therapy QIs (1996–97: 38, 2003–
04: 32) differed due to distinct risk categories.
Adherence indices
The application of defined QIs showed significant dif-
ferences of guideline adherence between 1996–97 and
2003–04 (see Table 3). The relative share of guideline-
adherent surgical treatments increased from 28.7 %
(1996–97) to 52.8 % (2003–04) in the institutional-
invasive sample (from 30.3 to 51.9 % in the regional-
invasive sample). Chemotherapy adherence increased
from 74.5 to 93.2 % (76.9 to 92.1 %) of treatments and
hormone therapy from 70.1 to 84.4 % (68.1 to 83.8 %).
Only the therapy sequence of lymph node dissection failed
to exhibit a significant difference between cohorts due to
the high quality level prior to infrastructural changes.
The summarizing overall binary adherence index
among all of the measured inpatient therapy sequences
significantly increased from 13.3 % (1996–97) to 35.2 %
(2003–04) in the institutional-invasive samples and from
15.1 to 33.5 %. In other words, a two-fold increase of
process quality has been achieved and the relative share of
treatments divergent from guidelines declined from 86.7
to 64.8 % (84.9 to 66.5 %).
Multivariate 5-year survival estimates
Period-specific results
Furthermore, the impact of the overall binary adherence
index on survival should be measured. Several steps of
model selection-, check- and model-fit-procedures identi-
fied a relevant covariate set encompassing the developed
adherence index. Estimates of the final Cox-regression
model are shown in Table 4.
Table 4 shows cohorts and samples across the statis-
tical information. For cohort 1996–97, both samples (in-
stitutional- and regional-invasive) show the negative
association between adherence index and survival. If a
patient was treated according to the guidelines, the
temporary affinity to die (hazard ratio) declined and
the 5- year overall survival increased. However, this re-
sult is not significant. A systematic effect of adherence
on survival is not evident. This result is consistent
across cohort 2003–04 and defined samples. The related
survival curves of multivariate survival estimates should
be derived by the corrected group analysis (CGA) method.
The results are shown in Table 5.
If all of the additional variables of the Cox model are
taken together, the CGA method allows for estimating
survival rates and related curves [24]. The cohort- spe-
cific perspective and the institutional-invasive samples
are presented first. Cohort 1996–97 exhibits remarkable
survival differences between comparison groups (institu-
tional-invasive: 84.5 − 76.8 = 7, 7). However, confidence
intervals and related p-values indicated that the results were
not significant. The same result was obtained for cohort
2003–04. A small 5-year survival difference (87.7 − 86.3 =
1,4) was estimated. However, the survival curves behave
differently as Fig. 1a-b indicates.
Table 1 Selection from entry cohort to samples of analysis
Sample Cohort 1996–97 Cohort 2003–04 Total
N % N % N %
Entry cohort 389 100,0 488 100,0 877 100,0
./. loss-to-follow up 0 0,0 17 3,5 17 1,9
./. No stage information availablea 1 0,3 2 0,4 3 0,3
./. Stage 0b 22 5,7 33 6,8 55 6,3
./. Mx, M1c 20 5,1 26 5,3 46 5,2
./. Missings on marginal resectiond 1 0,3 12 2,5 13 1,5
Institutional-invasive sample 345 88,7 398 81,6 743 84,7
./. Non-residents 107 27,5 132 27,0 239 27,3
Regional-invasive sample 238 61,2 266 54,5 504 57,5
Legend: arefers to non-assessable stage information, bexcludes non tissue invasive tumors (pTis), cexcluded all non-assessable metastasis status or distant metastasis,
dpatients without any information are excluded
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Figure 1a on the left shows the development of cohort
1996–97. The survival curves start separating after 12
months and depart after 30 months. The survival curves
of guideline-divergent treated patients decline more than
patients treated according to guidelines. In comparison,
for cohort 2003–04 the survival differences between
groups are very small, and the decline occurred after 20
months and a less steep development for the guideline-
divergent treated patients was observed (Fig. 1b). If the
analysis is restricted to regional-invasive samples (e.g.,
residential patients), cohort 1996–97 displayed small sur-
vival differences (83.4 − 79.9 = 3.5, see Table 5) and cohort
2003–04 displayed considerable survival differences (91.0 −
84.0 = 7.0, see Table 5) between the comparison groups.
Figure 2a-b demonstrates insights.
Figure 2a shows the survival curve of cohort 1996–97.
It seems that the curves start to separate after 12 months,
and after 30 months the curve declines more. The survival
Table 2 Distribution of available risk, prognostic and predictive factors in selected samples of analysis
Institutional-invasive sample Test Regional invasive sample Test
Variables Statistic 1996–97 2003–04 p-value 1996–97 2003–04 p-value
Age at surgery mean (SD) 60.4 (13.1) 59.8 (13.8) n.s. 60.9 (13.3) 60.7 (14.1) n.s.
Cancerous lymph nodes = 0 N (%) 211 (61) 266 (67) n.s. 159 (67) 187 (70) n.s.
Cancerous lymph nodes = 1–3 N (%) 70 (20) 84 (21) n.s. 41 (17) 53 (20) n.s.
Cancerous lymph nodes > 3 N (%) 64 (19) 48 (12) n.s. 38 (16) 26 (10) n.s.
pN- N (%) 211 (61) 266 (67) n.s. 159 (67) 187 (70) n.s.
pN+ N (%) 134 (39) 132 (33) n.s. 79 (33) 79 (30) n.s.
pT1a (<= 0.5cm) N (%) 25 (7) 29 (7) n.s. 19 (8) 20 (8) n.s.
pT1b (>0.5-1cm) N (%) 40 (12) 70 (18) n.s. 25 (11) 44 (17) n.s.
pT1c (>1–2cm) N (%) 133 (39) 155 (39) n.s. 91 (38) 96 (36) n.s.
pT2 (>2cm–5cm) N (%) 112 (33) 123 (31) n.s. 77 (32) 90 (34) n.s.
pT3 (>5cm) N (%) 5 (2) 8 (2) n.s. 5 (2) 5 (2) N/A
pT4 (incl. other symptoms) N (%) 30 (9) 13 (3) n.s. 21 (9) 11 (4) n.s.
Invasiv-ductal MaCa N (%) 290 (84) 292 (73) 0.015 200 (84) 197 (74) n.s.
Invasiv-lobular MaCa N (%) 29 (8) 59 (15) n.s. 23 (10) 36 (14) n.s.
Others N (%) 26 (8) 59 (15) n.s. 15 (6) 33 (12) n.s.
Gx N (%) 1 (0) 7 (2) N/A 0 (0) 6 (2) N/A
G1 N (%) 23 (7) 50 (13) n.s. 20 (8) 36 (14) n.s.
G2 N (%) 165 (48) 282 (71) <0.001 108 (45) 186 (70) <0.001
G3 N (%) 156 (45) 59 (15) <0.001 110 (46) 38 (14) <0.001
ER+ N (%) 253 (73) 305 (77) n.s. 177 (74) 205 (77) n.s.
ER- N (%) 92 (27) 93 (23) n.s. 61 (26) 61 (23) n.s.
PR+ N (%) 266 (77) 285 (72) n.s. 183 (77) 189 (71) n.s.
PR- N (%) 79 (23) 113 (28) n.s. 55 (23) 77 (29) n.s.
ERPR+ N (%) 290 (84) 318 (80) n.s. 201 (85) 213 (80) n.s.
ERPR- N (%) 55 (16) 80 (20) n.s. 37 (16) 53 (20) n.s.
Rx N (%) 34 (10) 3 (1) N/A 23 (10) 2 (1) N/A
R0 N (%) 292 (85) 378 (95) <0.001 205 (86) 252 (95) <0.001
R1 N (%) 17 (5) 17 (4) n.s. 9 (4) 12 (5) N/A
R2 N (%) 2 (1) 0 (0) N/A 1 (0) 0 (0) N/A
Pre-Menopause N (%) 93 (27) 95 (24) n.s. 60 (25) 61 (23) n.s.
Post-Menopause N (%) 252 (73) 303 (76) n.s. 178 (75) 205 (77) n.s.
Chemotherapy planned N (%) 138 (40) 207 (60) n.s. 158 (40) 240 (60) n.s.
Clinic A + B N (%) 128 (37) 79 (20) n.s. 101 (42) 62 (23) n.s.
Clinic C N (%) 217 (63) 319 (80) <0.001 137 (58) 204 (77) <0.001
Legend: Several tests were not applicable (N/A) due to 20 % of cells with less than five cases, p-values adjusted for multiple testing
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Table 3 Guideline-adherent treated breast cancer inpatients per therapy sequence and distribution of guideline divergences
N (%) Institutional-invasive samples Regional invasive samples
1996–97 2003–04 p-valuea 1996–97 2003–04 p-valuea
Surgical strategy incl. irradiation 99 (28.7) 210 (52.8) <0.001 72 (30.3) 138 (51.9) <0.001
Lymph node dissection 279 (80.9) 323 (81.2) n.s. 188 (79.0) 209 (78.6) n.s.
Planned chemotherapy 257 (74.5) 371 (93.2) <0.001 183 (76.9) 245 (92.1) <0.001
Planned hormontherapy 242 (70.1) 336 (84.4) <0.001 162 (68.1) 223 (83.8) <0.001
Adherence overall 46 (13.3) 140 (35.2) <0.001 36 (15.1) 89 (33.5) <0.001
Divergence overall 299 (86.7) 258 (64.8) 202 (84.9) 177 (66.5)
Legend: All tests are adjusted for multiple testing, (n.s.) non-significant test results
Table 4 Multivariate Cox-regression models applied to the adherence index and crucial risk, prognosis and predictive factors
Regressors Beta Standard Test Hazard- 95 % confidence interval
coefficient error P-value ratio Lower bound Upper bound
Cohort 1996–97, Institutional-invasive sample
Adherence index −0.373 0.436 0.392 0.688 0.293 1.619
Age at surgery −0.044 0.069 0.525 0.957 0.836 1.069
Nodal status (pN-, pN+) 1.049 0.263 <0.001 2.854 1.706 4.775
Tumor size (pT2, pT2-pT4) 0.121 0.244 0.620 1.129 0.700 1.821
Hormon receptor status (ERPR+, ERPR-) 0.602 0.313 0.055 1.825 0.988 3.371
Quadratic term of age at surgery 0.001 0.001 0.132 1.001 1.000 1.002
Cohort 1996–97, Regional-invasive sample
Adherence index −0.162 0.489 0.740 0.850 0.326 2.217
Age at surgery −0.058 0.083 0.483 0.943 0.801 1.111
Nodal status (pN-, pN+) 1.184 0.336 <0.001 3.269 1.692 6.316
Tumor size (pT2, pT2-pT4) 0.015 0.307 0.961 1.015 0.556 1.854
Hormon receptor status (ERPR+, ERPR-) 0.664 0.389 0.088 1.942 0.907 4.162
Quadratic term of age at surgery 0.001 0.001 0.188 1.001 1.000 1.002
Cohort 2003–04, Institutional-invasive sample
Adherence index −0.135 0.350 0.699 0.873 0.440 1.733
Age at surgery −0.089 0.080 0.266 0.915 0.782 1.070
Nodal status (pN-, pN+) 0.931 0.307 0.002 2.537 1.391 4.627
Tumor size (pT2, pT2-pT4) 0.615 0.302 0.042 1.850 1.023 3.344
Hormon receptor status (ERPR+, ERPR-) 1.196 0.310 <0.001 3.307 1.801 6.075
Quadratic term of age at surgery 0.001 0.001 0.173 1.001 1.000 1.002
Cohort 2003–04, Regional-invasive sample
Adherence index −0.638 0.467 0.172 0.529 0.212 1.320
Age at surgery −0.151 0.090 0.093 0.859 0.720 1.025
Nodal status (pN-, pN+) 0.500 0.375 0.182 1.648 0.791 3.437
Tumor size (pT2, pT2-pT4) 0.512 0.371 0.168 1.668 0.806 3.450
Hormon receptor status (ERPR+, ERPR-) 1.048 0.367 0.004 2.853 1.389 5.861
Quadratic term of age at surgery 0.001 0.001 0.070 1.001 1.000 1.003
Legend: Confidence intervals (CI) with lower bounds (LB) and upper bounds (UB), planned chemotherapy (no, yes) and location of treatment (clinics A + B, C) were
used as strata variables
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curve of cohort 2003–04 (Fig. 2b) exhibits a different
pattern. The survival curve starts departing from the
beginning of the observation time and the curve of
guideline-divergent treated patients is steeper after 10
months. Thus, the survival curves of cohorts and samples
were altered substantially in terms of survival level and
curve developments.
Cross-period results
To obtain more insights into cross-period survival rates
and patterns, the cohorts were compared regardless of
adherence status (not shown in tables). The institutional-
invasive sample estimated a survival rate of 79 % for co-
hort 1996–97 and 86 % for cohort 2003–04. The survival
difference between cohorts was significant (p = 0.007).
However, if the information of guideline adherence is
added to the model and cross-period survival curves of
guideline-adherent only, or guideline-divergent treated
patients only were estimated, the subject becomes more
intriguing.
First, if only guideline-adherent patients of the
institutional-invasive samples were compared, the survival
Table 5 Multivariate 5-year survival and event rates estimated by the corrected group analysis method
Cohort Survival Event Hazard 95 % confidence interval Test
Samples Comparison groups rate rate ratio Lower bound Upper bound p-value
1996–97 Institutional-invasive Guideline divergence 76.8 23.2 1.612 0.690 3.766 n.s.
Guideline adherence 84.5 15.5
1996–97 Regional-invasive Guideline divergence 79.9 20.1 1.293 0.500 3.348 n.s.
Guideline adherence 83.4 16.2
2003–04 Institutional-invasive Guideline divergence 86.3 13.7 1.147 0.581 2.266 n.s.
Guideline adherence 87.7 12.2
2003–04 Regional-invasive Guideline divergence 84.0 16.0 1.914 0.772 4.745 n.s.
Guideline adherence 91.0 9.0
Guideline-adherence Institutional-invasive 1996–97 89.6 10.4 1.036 0.333 3.229 n.s.
2003–04 89.9 10.1
Guideline-adherence Regional-invasive 1996–97 87.1 12.9 1.922 0.453 8.161 n.s.
2003–04 92.2 7.8
Guideline-divergence Institutional-invasive 1996–97 76.4 23.7 1.665 1.113 2.490 0.013
2003–04 84.6 15.4
Guideline-divergence Regional-invasive 1996–97 79.6 20.4 1.196 0.734 1.947 n.s.
2003–04 82.5 17.5
Legend: First row of each comparison yields higher hazard and lower/equal survival (effect coding)
Fig. 1 Institutional-invasive samples comparing guideline-adherent and -divergent treated patients. Cohort 1996–97 (left) and cohort
2003–04 (right)
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estimates (see Table 5) were almost identical for co-
horts 1996–97 and 2003–04 (89.6 % vs 89.9 %). The
survival differences were not significant. If this com-
parison is restricted to residential patients (e.g., the
regional-invasive sample), the survival rate of cohort
1996–97 was essentially lower than in cohort 2003–04
(87.1 % vs 92.2 %) but still not significant. Figure 3a-b
shows the survival curves.
Second, only guideline-divergent treated patients were
observed across the samples. The institutional-invasive
samples showed a survival rate of 76.4 % in cohort
1996–97 and 84.6 % for cohort 2003–04 (see Table 5).
This difference was significant (p = 0.013). However, this
result was not replicated for the regional-invasive sam-
ples (79.6 vs 82.5; not significant). The survival curves
are shown in Fig. 4a-b.
Discussion
Based on the defined set of quality indicators according
to time dependent guidelines and available medical
knowledge, a two-fold increase of process quality and its
medical decision making from the expert’s point of view
has been observed. This result is a benefit for women
with BC because the complexity of modern therapies
continues to grow.
Period-specific comparisons
The process quality of cohort 1996–97 was expected to
be low, and no survival differences between comparison
groups in cohort 1996–97 were expected. In fact, no
impact of process quality on survival was observed. For
cohort 2003–04, a higher clinical process quality was
hypothesized and an impact on survival was expected.
Fig. 2 Regional-invasives samples comparing guideline-adherent and -divergent treated patients. Cohort 1996–97 (left) and cohort
2003–04 (right)
Fig. 3 Guideline-adherent treated patients of cohort 1996–97 and cohort 2003–04. Comparison of institutional-invasive (left) and regional-invasive
samples (right)
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Higher survival rates of the guideline adherence group
were expected but were not observed. Multivariate sur-
vival analysis revealed no significant associations of the
adherence index on 5-year overall survival across all of
the defined samples.
Cross-period comparisons
The cross-period/cohort comparisons should yield deeper
insights into mechanisms of temporal changes. Cross-
period comparisons without considering the overall binary
adherence index showed a significant difference of survival
rates of approximately 7 % (see subsection ’Cross-period
results’). However, cross-cohort comparisons of the adher-
ence group only showed that estimates revealed no signifi-
cant survival differences. When the guideline divergence
group of cohort 1996–97 and 2003–04 were compared,
systematic survival gains of 10 % were observed for the
institutional-invasive sample. The latter survival increase
exceeds the survival increase of periods regardless of the
adherence status by approximately 3 %. This excess sur-
vival can be characterized as a period effect and was not
expected for this subgroup.
In the context of guideline developments and its assess-
ment, this unraveled period effect was deemed inconsistent
with the ubiquitous demand of the maximization of guide-
line adherence [17, 18]. Isn’t it a paradox that particular
women with BC benefited most in the last decade from
treatment which violated guideline recommendations?
Essence of guidelines
It is not inconsistent with the essence of guidelines be-
cause the identified paradox reflects the very nature of
guidelines as they should apply for the vast majority of
patients. Schulz et al. [10] emphasized that “if the indi-
vidual situation requires deviations of guidelines, it is
not solely possible, it is mandatory to do so. Guidelines
do not discard physicians from their obligation to con-
cern the clinical characteristics, somatic, psychological
and social conditions of each patient”.
At this point, cohort 1996–97 and 2003–04 differ sub-
stantially from the infrastructural perspective. Systematic,
rationale and conscious decisions against guidelines were
made and monitored by expert panels in 2003–04.
Why adherence paradox?
These multidisciplinary expert panels were introduced in
the decade of cohort 2003–04 to cope with the essence
of guidelines. Expert panels operated by leading physi-
cians from all related disciplines (e.g., gynaecologist,
oncologists, surgeons, pathologists, radio-oncologists,
psycho-oncologists, etc.) gave consensual advice for
further, multi-modal treatment [11]. Expert panels became
an important forum to consider guideline recommenda-
tions, individual medical experience of various experts,
patient preferences and their social circumstances. Expert
panels use guidelines as a starting point for common rec-
ommendations and, if necessary, violate them systematic-
ally, rationally and consciously to tailor an individualized
therapy. Thus, the identified adherence paradox reflects
this essence of guidelines and signalizes its appropriate
application in certified BC networks [15].
Alternative approaches to define an adherence index
In comparison to related studies, most of these studies
use a rate-based/criterion-based approach to define 5 to
20 quality indicators, mostly extracted from routine data
[25–30]. These studies estimate that guideline adherence
is between 80 and 100 %. If 33 indicators are used, the
adherence of medical decisions decreases to 52 % [17, 18].
If medical decisions documented in patient record files are
Fig. 4 Guideline-divergent treated patients of cohort 1996–97 and cohort 2003–04. Comparison of institutional-invasive (left) and regional-invasive
samples (right)
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revised, 19 % (1993) and 54 % (1995) of 375 medical deci-
sions appear to be adherent with current guidelines [31].
Scientifically legitimated deviations increased from 42 %
(1993) to 68 % (1995). As an experimental design with
the same methodology was conducted, a non-significant in-
crease of 36 % (1996) to 40 % (1999) of 825 revised medical
decisions was found [32]. Overall, the degree of adherence
strongly depends on the length of observation time [33],
age of the patient [34], number of quality indicators
and included therapy sequences.
Adherence index and survival of related studies
Most studies only refer to selected therapy sequences
(e.g., surgery, chemotherapy, etc.) [35, 36] and dismiss
effects of relevant or related interventions. Other studies
assessed inpatient therapy by a small number of indicators
and estimated 50 % lower hazard ratios induced by guide-
line adherence treatment [37]. Woeckel et al. reproduced
this result with a greater number of indicators but advised
that a non-linear relationship between adherence and sur-
vival seems to be persistent [17, 18]. Indeed, the influences
of the socio-economic status (SES) seem to modify treat-
ment effects because social disparities of survival have
been reported [38, 39]. Hence, systematic positive and lin-
ear relationship of adherence and survival is not replicable
with incomplete multivariate models. In this sense, the
present study is consistent with other reports [40, 41].
Strengths of study
Data quality assessment prior to this study [19–21] as-
sured high data quality, epidemiological relevance, and
reliable and valid survival estimates. Sample distinction
between all selected patients and residential patients em-
phasizes that confounding effects and related biases were
adjusted for survival analyses. The definition of quality
indicators is based on “pathways of coherent decisions”
and is superior to the rate-based/criterion-based method-
ology. For example, breast conserving surgery/mastectomy
(BCS/MRM) together with irradiation (RAD) defines a
compound therapy according to the guidelines [12]. As
this approach was applied to time-interval specific guide-
lines, this study was able to identify the (unexpected)
period effects.
Limitations of the study
A number of the 104 quality indicators did not include
important variables necessary for guideline assessment.
Particularly, patients’ preferences for treatment strategies
are missing. Studies have shown that up to 50 % of patients
disagree with physicians’ treatment recommendations [42].
This comparatively high share of disagreement between pa-
tients (mastectomy preference) and their physicians (fa-
voring breast conserving therapy) referring to a sample
recruited between 2001 and 2003 emphasizes that
guideline deviations do not descend from medical experts
alone. Additionally, some indicators refer to decisions and
planned actions but not to actual “clinical performance”.
This limitation refers to chemo- and hormone-therapies
whose time schedules strongly depend on the patients’
physical conditions. To consider this general flaw of
conceptualization, new categories such as “scientifically
legitimate decisions” [31, 32] or “justifiable guideline
divergence” decisions [43] seem to be more appropriate
to relax the rigid distinction between guideline adherence
and divergence.
Conclusions
The proof of a positive relationship of guideline adherence
and survival seems to be more complex than understood so
far. Unexpectedly, guideline-divergent treated patients of
cohort 2003–04 benefited most. We hypothesized that in-
frastructural efforts made by multidisciplinary expert panels
contributed to this adherence paradox. The adherence
paradox reflects the essence of guidelines and signalizes ap-
propriate application of guidelines in certified BC networks.
The maximization of guideline-based decisions should sub-
stitute the postulation of adherence maximization. Finally,
if women recognize treatment deviations from published
patient guidelines for BC, the prognosis of therapy is no
longer associated with shorter survival.
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